CVR Medical Provides TUV Safety Testing Update

CVR Medical Corp. (OTCQB:CRRVF)

DENVER, NC, USA, December 13, 2018 /EINPresswire.com/ —

CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector announces that its patented, disruptive Carotid Stenotic Scan (CSS) has passed the IEC 60601-1-2 edition 4, General Requirements for Basic Safety and Essential Performance – Electromagnetic Disturbances conducted by TUV Rheinland of North America. TUV Rheinland of North America, is one of the leading providers of product safety certifications worldwide, covering an assortment of items such as medical devices, home appliances, audio/video products, medical products, textiles and telecommunication equipment. This testing is required for the CSS’s subsequent De Novo submission to the FDA for US market clearance and will show that the device is compliant with all IEC 60601-1-2 EMC requirements. The International Electrotechnical Commission (IEC), based in Geneva, Switzerland, publishes the 60601 series of technical standards that allow medical device developers to demonstrate the safety and essential performance of their medical equipment. Upon completion of EMC testing, TUV North America started IEC 60601-1 safety testing which includes, software and hardware validation , fire and electrical safety and mechanical failure. As announced, CVR’s previous guidance relating to FDA submission remains unchanged for Q1 2019.

In speaking to CVR’s VP of Program Management & Product Development, Lewis Crenshaw, the TUV engineer stated “CVR’s team did a tremendous job preparing documentation and hardware for IEC 60601-1-2 EMC safety testing. This allowed the TUV team to quickly and efficiently tackle the testing, review technical documents and draft and sign the EMC test report during the busiest time of our year.”

Tony Robinson, CVR Medical’s Chief Operating Officer stated, “This represents one of the final hurdles standing between CVR and the FDA submission that we have been working so diligently towards. Many companies are significantly delayed by requirements such as EMC, but thanks to the thoroughness of the CVR engineering team and open dialogue which TUV provided, we have been able to maintain our momentum toward our objectives. Working with TUV has been the epitome of efficiency and effectiveness, even during this extraordinarily busy time. We know that when our CSS device is placed into the clinical setting we are holding ourselves to the industry’s highest standard of electrical safety.”

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan (CSS). The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in pivotal clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Chairman

For further information contact:
Peter Bakema, CEO, President and Chairman
Email: info@cvrmed.com
or
Marc S. Lubow.
Vice President Capital Markets, Director Investor Relations
904-923-4037
marclubow@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Marc Lubow
CVR Medical Corp.
+1 904-923-4037
email us here


Source: EIN Presswire

Dr. Michael Iwama is Named Dean at MGH Institute of Health Professions in Boston

Dr. Michael Iwama, Dean, MGH Institute of Health Professions

Dr. Michael Iwama is the new Dean of the School of Health and Rehabilitation Sciences at MGH Institute of Health Professions in Boston.

Widely recognized for developing the "Kawa Model" of care, Dr. Iwama is a progressive thinker in the fields of occupational therapy and rehabilitation sciences.

I really want to be able to contribute to a legacy, work with colleagues to achieve something truly great, and give something back to the world, and I want to do it at the MGH Institute.”

— Dr. Michael Iwama, Dean, MGH Institute of Health Professions

BOSTON, MA, USA, December 13, 2018 /EINPresswire.com/ — Michael Iwama, PhD, MSc, BScOT, has been named the new Dean of the School of Health and Rehabilitation Sciences, and Professor in the Department of Occupational Therapy, at MGH Institute of Health Professions graduate school in Boston.

Dr. Iwama is widely recognized for having developed the “Kawa Model” (‘Kawa’ is Japanese for ‘River’), the first substantial model of practice in the rehabilitation sciences developed outside the English-speaking world. The Kawa Model is now taught in over 600 health professions education programs internationally and used in practice across six continents. He has emerged as a very important and progressive thinker in the fields of occupational therapy and rehabilitation sciences worldwide.

“I’m at that stage in my career where I really want to be able to contribute to a legacy, work with colleagues to achieve something truly great, and give something back to the world,” says Dean Iwama, who was born in Japan and grew up in Canada. “And I want to do it at the MGH Institute.”

Iwama draws on his rich experience of acculturating into Eastern and Western social spheres of experience to drive his profound and critical perspectives on culture and its intersections with theory and practice in the rehabilitation sciences.

A passionate and captivating communicator, Dean Iwama regularly is invited to lecture to both U.S. and international audiences. Since his book, The Kawa Model: Culturally Relevant Occupational Therapy, was published in 2006, he has given over 350 invited national and international lectures and over 40 keynote and plenary addresses at scientific and professional conferences. He has more than 25 publications in both English and Japanese professional journals.

“We are absolutely thrilled that an educator and scholar with such impressive credentials has joined the MGH Institute,” said President Paula Milone-Nuzzo, PhD, RN, FHHC, FAAN. “Dr. Iwama’s record of accomplishment is known throughout the world, and our programs in genetic counseling, occupational therapy, physical therapy, physician assistant studies, and speech-language pathology will thrive under his leadership.”

Iwama also is an adjunct professor in the Faculty of Medicine at the University of Toronto and holds similar adjunct professorial appointments at six universities in Canada, the United Kingdom, Australia, and Asia.
Prior to arriving at the MGH Institute, he was professor and chair of the Department of Occupational Therapy at Augusta University, formerly the Medical College of Georgia.

Iwama completed advanced studies in Medical Anthropology from University of Leiden, Netherlands, and has earned a PhD in Sociology from Kibi International University in Japan, a MSc in Rehabilitation Sciences from University of British Columbia, a BSc in Occupational Therapy from University of British Columbia, and a BSc in Human Performance from the University of Victoria.

About MGH Institute of Health Professions
Team-based care, delivered by clinicians skilled in collaboration and communication, leads to better outcomes for patients. That’s why MGH Institute of Health Professions graduate school in Boston integrates interprofessional education into its academic programs. Approximately 1,600 students at its Charlestown Navy Yard campus learn and collaborate in teams across disciplines as they pursue post-baccalaureate, master’s, and doctoral degrees in genetic counseling, nursing, occupational therapy, physical therapy, physician assistant studies, speech-language pathology, health professions education, and rehabilitation sciences. Its interprofessional learning model extends to hundreds of hospital, clinical, community, and educational sites in Greater Boston and beyond.

The MGH Institute is the only degree-granting affiliate of Partners HealthCare, New England’s largest health provider. It has educated more than 7,700 graduates since its 1977 founding. It is fully accredited by the New England Commission of Higher Education. Several programs are highly ranked by U.S. News & World Report. For the past nine years, the IHP has been named a "Great College to Work For” by The Chronicle of Higher Education.

John Shaw
MGH Institute of Health Professions
617-726-4276
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn


Source: EIN Presswire

Vitality Men's Center Opens First Medical Clinic in Idaho to Offer Testosterone Therapy via Telemedicine

Vitality Men’s Center is a medical clinic that focuses on the treatment of men with low testosterone. Our clinic offers a telemedicine option for appointments.

“34% of men over 45 have low testosterone.” – Dr. Getz”

— Dr. Daniel Getz

DALTON GARDENS, ID, USA, December 13, 2018 /EINPresswire.com/ — Vitality Men’s Center has just opened the first medical clinic in Idaho to offer testosterone therapy using advancements in telemedicine. The clinic, co-founded by chief physician Dr. Dan Getz, provides 100 percent virtual low-testosterone treatment including both testosterone replacement therapy and testosterone regeneration therapy. Dr. Getz is now one of the first male hormone specialists to offer 100 percent virtual low testosterone therapy. Learn more www.vitalitymenscenter.com

Vitality Men's Center Team
Vitality Men's Center
+1 208-565-1821
email us here
Visit us on social media:
Facebook

Learn more about Low T.


Source: EIN Presswire

MEDOCTOR developing ASIA TELEHEALTH MARKET

MEDOCTOR SYSTEM IS BEING SUCCESSFULLY DEPLOYED IN ASIA

JACKSONVILLE, FLORIDA, USA, December 13, 2018 /EINPresswire.com/ — MEDOCTOR developing ASIA TELEHEALTH MARKET

The Medoctor System is being successfully deployed in Asia.

Medoctor is providing users in India, Pakistan, the Philippines, Vietnam and people throughout Asia with the opportunity to do a health assessment, free-of-cost and create a personal health record. Anyone with a health problem, pain or discomfort can click on www.medoctor.com and determine their health situation – without payment.

Young mothers using cellphones are the largest market, they need to care for their children, spouse and sometimes parents. Over 70% of Medoctor users access www.medoctor.com on their iPhone or Android, others use tablets or laptops.
Users answer simple YES / NO symptom questions generated by the Medoctor Engine to produce a complete differential diagnosis. The Medoctor user can save the results to show or email to their family doctor. Medoctor's motto is "Assisting Physicians Worldwide".

Family physicians dramatically increase their daily throughput with the extensive results produced by the Medoctor System. Using the patient's time to save the clinician's time, an electronic health record is created automatically – a cost and time saving for both the doctor and the patient.

Medoctor is interested in creating relationships with medical professionals and health institutions, including pharmacies and advertisers. Contact info@medoctor.com .

Medoctor has been demonstrated at the World Health Organization in Geneva and the International Telecommunication Union sponsored a pilot for Medoctor at a Women-Led-Telecentre in Zambia. Clinical trials of Medoctor were conducted in Vietnam.

Financial institutions and healthcare organizations are invited to contact Medoctor, Inc., a USA corporation, regarding partnership, participation or representation. Qualified parties are invited to contact ceo@medoctor.com to arrange a discussion on Skype – address medoctorceo.

Charles W. Kelly
Medoctor, Inc.
239-784-3776
email us here


Source: EIN Presswire

Green Relief Inc. Appoints New Chief Financial Officer

Andrew Pegg

Green Relief

Mr. Pegg joins Green Relief from Spin Master, a global toy and entertainment company

With Green Relief's unique use of aquaponics to produce its products, and a purpose-driven and passionate team behind me, I look forward to working on the cutting edge of an exciting industry.”

— Andrew Pegg

HAMILTON, ON, CANADA, December 13, 2018 /EINPresswire.com/ — Green Relief Inc., Canada's leading licensed producer of medical cannabis using aquaponics as a growing method, announced today the appointment of Andrew Pegg as the company's Chief Financial Officer.

"We're thrilled to welcome Andrew as our new CFO," says Warren Bravo, Chief Executive Officer, Green Relief Inc. "Andrew brings extensive finance and operational experience to our company. This, coupled with Andrew's big-picture thinking, will be an asset as Green Relief takes strides to expand its business, and transitions into a public company in early 2019."

Mr. Pegg joins Green Relief from Spin Master, a global toy and entertainment company headquartered in Toronto, where he served as Vice President of Finance since 2013.

Previously, Mr. Pegg was the Vice President of Finance and Business Planning for Latin America and Canada at Revlon, an international company specializing in cosmetic, skin-care, fragrance, and personal-care products.

Mr. Pegg began his career as a Financial Analyst at Citytv, and has since held progressively senior finance roles with a number of top-tier companies, including PepsiCo and Corby Spirit and Wine.

At Green Relief, Mr. Pegg will play a critical role in the strategic direction of the company's finances as it scales up its production of medical cannabis to better serve a rapidly growing patient-base.

"With Green Relief's unique use of aquaponics to produce its products, and a purpose-driven and passionate team behind me, I look forward to working on the cutting edge of an exciting industry," Mr. Pegg says.

Presently, Green Relief operates from a 30,000-square-foot facility in Hamilton. Plans for expansion include the recent acquisition of a 100,000-square-foot production facility in Stoney Creek, Ont., which will increase the company's annual output from 2,800 kg to about 17,800 kg.

Construction of a 240,000-square-foot production facility at the company's original Hamilton site is also underway, as is a 25,000-square-foot facility on an adjacent property that will be used for research and development.

"With robust plans for expansion in place, Andrew's appointment to CFO is timely, and will help drive Green Relief's success into the near, and distant, future," Mr. Bravo says.

-30-

About Green Relief

Based in Hamilton, Ont., Green Relief is Canada's leading licensed producer of medical cannabis using aquaponics to sustainably grow its plants. Aquaponics is a closed-loop system that combines aquaculture (raising fish) with hydroponics (the soilless cultivation of plants). As a result, aquaponics uses up to 90 per cent less water than conventional agriculture, while also producing 10 times the crop yield per hectare, and an end product free from synthetic fertilizers and harmful pesticides. Additionally, once the system's fish reach market size, Green Relief donates the protein source to a food rescue service that delivers meals to those in need. Over the last three years, Green Relief has donated more than 40,000 fish through this initiative. At Green Relief, the mission is simple: helping patients improve their quality of life while also being environmentally responsible, and giving back to the community.

Media contact

Chris Binet, Publicist
Blend PR
chris@blendpr.com
www.blendpr.com
+1-416-907-0977 ext. 4

Chris Binet
Blend PR
+1 4165670977
email us here


Source: EIN Presswire

Melamedia Webinar to Include First Look at OCR's Thoughts on Changing HIPAA Rules

Melamedia's 15th Annual Year-End Review of Medical Privacy and Security Enforcement Features Discussion by HIPAA Veterans

ALEXANDRIA, VA, US, December 13, 2018 /EINPresswire.com/ — The HHS Office for Civil Rights just released a request for information on changes that "may impede the transformation to value-based healthcare or that limit or discourage coordinated care among individuals and covered entities."

So Melamedia's 15th Annual Year-End Review of Medical Privacy & Security Enforcement has added a discussion to explore OCR's thoughts on possible changes to HIPAA and what that may mean for future compliance.

The event features long-time veterans in the HIPAA space.

FACULTY

Iliana Peters served key roles at HHS Office for Civil Rights, including as OCR’s Acting Deputy Director for Health Information Privacy and Security and as OCR’s Senior Advisor for HIPAA Enforcement. For more than a decade, she both developed HIPAA privacy and security policy, including on emerging technologies and cyber threats, and enforced HIPAA regulations through spearheading multi-million-dollar settlement agreements and civil monetary penalties under HIPAA. She is a shareholder in the nationally-recognized health care practice group of the AmLaw 100 law firm, Polsinelli, P.C.

Dennis Melamed is president of Melamedia, LLC, a regulatory analysis and research firm. He is an adjunct professor at the Drexel College of Medicine where he teaches graduate level courses on health data stewardship, federal regulation of biomedical research and trends in medical device regulation. Dennis works extensively as a regulatory affairs analyst and researcher and has served as consultant on health data stewardship issues for a number of organizations, including the National Governors Association's State Alliance for E-Health. He is the editor and publisher of Health Information Privacy/Security Alert, which has been tracking health data privacy and security issues since 1997.

Katalin Sugar
Melamedia
email us here
+1 703-704-5665


Source: EIN Presswire

Genentech develop Antibiotic effective against Gram-negatives, with potential to lead to new class of Antibiotics

Superbugs & Superdrugs 2019

Superbugs & Superdrugs 2019

Biotech Genentech, discoverers of a promising new antibiotic, set to speak at Superbugs & Superdrugs 2019 Conference in London, UK on 18th – 19th March 2019

LONDON, LONDON, UNITED KINGDOM, December 13, 2018 /EINPresswire.com/ — Despite international efforts to reduce the increasing threat of antibiotic resistance, multi-drug resistant bacteria are continuing to endanger the global population.

Next year's Superbugs & Superdrugs conference, taking place 18th – 19th March in London, aims to explore the efforts of industry-leading organisations in the field, discussing the latest developments in novel therapeutics, antifungals, funding, regulation, and more.

Gram-negative bacteria are considerably the most concerning antibiotic-resistant bacteria, as they have two membranes antibiotics need to penetrate. For a long time, no new classes of antibiotics effective against Gram-negatives had been approved in over fifty years.

However, in recent news US biotech Genentech have developed a molecule called G07750 which has proven effectiveness against several Gram-negative bacteria that are resistant to nearly all marketed antibiotics.* Genentech hopes this discovery will lead to a new class of antibiotics to help aid the fight against the continuous struggle against antimicrobial resistance.

Delegates attending the Superbugs & Superdrugs conference next year in 2019 will have the exclusive opportunity of hearing from Genentech’s Senior Scientist Michael Koehler, who is set to speak and present at the 21st annual event on “Optimized Arylomycins represent a new class of Gram-Negative Antibiotics”.

Michael’s presentation will be focusing on the topics of:

• Chemical optimization of the arylomycins to obtain G0775, a molecule with potent, broad-spectrum activity against Gram-negative bacteria
• G0775 inhibits the essential bacterial type I signal peptidase
• It circumvents existing antibiotic resistance mechanisms and retains activity against contemporary multidrug-resistant Gram-negative clinical isolates
• Optimized arylomycin analogues such as G0775 could translate into new therapies to address multidrug-resistant Gram-negative infections

The development of novel antibiotics is crucial to fighting the war on antibiotic resistance as current treatments fail to effectively treat even the most common and usually innocuous bacterial infections.

Next year’s two-day conference will gather an international speaker line-up to explore the latest advancements in new antimicrobial agents, as well as potential alternatives to antibiotics including immunotherapies, precision antibiotics, and much more.

Download the brochure on the event website to view the agenda and speaker line-up at http://www.superbugssuperdrugs.com/einpr.

Book your place before 14th December to save £200, or 31st January to save £100.

Superbugs & Superdrugs
18th & 19th March 2019
London, UK

*fiercebiotech.com

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
+44 207 827 6124
email us here


Source: EIN Presswire

Bachelorette’s Garrett Yrigoyen Steps into the Outdoor World with Gage Outdoor Expeditions

Bachelorette Season 14 winner Garrett Yrigoyen teams up with Gage Outdoor Expeditions, a premier booking agent, for a series of hosted hunting & fishing trips.

MINNEAPOLIS, MINNESOTA, UNITED STATES, December 13, 2018 /EINPresswire.com/ —
(Minneapolis, MN): Gage Outdoor Expeditions, a global leader in brokering hunting and fishing trips around the world, announces the launch of its hosted events featuring Garrett Yrigoyen, winner of the Bachelorette Season 14. Garrett, an avid fisherman and upland hunter, will be hosting multiple trips around the world this year with Gage and their professional guides and outfitters. Stay tuned for the specific locations and itineraries. Possible excursions include pheasant hunting at the historic Thunderstik Lodge in Chamberlain, SD; fishing at one of our remote lodges in Canada or Alaska; Africa Safaris; Argentina dove hunting and more. Wherever Garrett is, Bachelorette Becca is not far away, so keep your eye peeled for a possible plus one.

In addition to launching hosted trips, Gage Outdoor Expeditions has other exciting new projects in the works including its “Hunt to Table” gourmet program, Rescue Dog Re-Homing of Hunting Dogs Program, new experience-based trips and Next Generation (multi-gen) programming.

Garrett Yrigoyen Bio: California native, Garrett Yrigoyen, discovered his love for the great outdoors as a young boy when his parents would take his family on camping trips in the nearby Sierra Nevada mountains. It was there, at the age of 4, where his addiction to reel-in fish began. A handful of years later, Garrett began hunting dove and pheasant in the very fields that his father farmed. For a number of years education and sports took precedence over the opportunity to hunt and fish. In 2007 he was the male senior all-around athlete for Sierra High School in Manteca, CA. In junior college, he started at third base for the San Joaquin Delta College Mustangs baseball team who placed second at the California state championship. He then moved on to the University of Nevada Reno where he obtained a degree while starting each year at third base for the Wolfpack baseball team. While living in Nevada, he developed a passion for hunting chukar high up in the mountains and fly fishing on local rivers, streams, and lakes chasing rainbow, brown, golden and Lahontan cutthroat trout. He was the last man standing on Season 14 of ABC’s the Bachelorette with Becca Kufrin and is now pursing his passion for fishing and hunting with us at Gage Outdoor.

About Big Hat Outdoors: Big Hat Outdoors, LLC is the parent company of Gage Outdoors founded by of John and Kimberly Kalan of Minneapolis, Minnesota. Big Hat includes Thunderstik Lodge, located in Chamberlain, South Dakota, along the banks of the Missouri River. Big Hat’s other brands are Rooster Ridge Hunting Lodge (also in Chamberlain), Gage Outdoor Expeditions, and High Profile Grounds Maintenance and Green Solutions (Minneapolis). www.gageoutdoor.com

Read more about Garrett and check out his 1st event at Historic Thunderstik Lodge. https://gageoutdoor.com/hunt-with-garrett-yrigoyen/

Mercy Sells
Gage Outdoor Expeditions
+1 6192522001
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire

Tosk Announces kRAS Presentation at AACR Meeting

Drug developer Tosk, Inc.,

Tosk, U.S. National Cancer Institute's (NCI) Frederick National Laboratory and the Texas Tech Health Sciences Center makes joint presentation in San Diego

This innovative work on the discovered inhibitor provided important information on the previously, not fully appreciated, interplay between mutated kRAS and a metabolic process.”

— William Garland, Vice President, Research & Development

MOUNTAIN VIEW, CALIFORNIA, USA, December 13, 2018 /EINPresswire.com/ — Privately held biotechnology company, Tosk, Inc., announced today a joint presentation with the U.S. National Cancer Institute's (NCI) Frederick National Laboratory and the Texas Tech Health Sciences Center (TTHSC) at a meeting this week in San Diego, CA. The meeting, entitled “Targeting RAS-Driven Cancers,” was sponsored by the American Association for Cancer Research (AACR). The presentation was entitled “kRAS and Metabolism: An Interesting Interplay.”
Mutations in the human kRAS gene drive 90% of pancreatic cancers, 45% of colon cancers, and 35% of lung cancers. Patients with certain mutated kRAS genes also do not benefit from treatment with a widely-used class of cancer drugs known as EGFR inhibitors, such as Erbitux®. An effective inhibitor of mutated kRAS would address these unmet medical needs and provide an important, new treatment for cancer.
Tosk features proprietary discovery technology using the common fruit fly to discover potential kRAS-inhibiting drugs. This discovery platform uses fruit files with a mutated human kRAS gene integrated into their genome, causing the fly’s wings to be crimped. Tosk screens for drugs which reverse this wing crimping by inhibiting the protein produced by the mutated kRAS gene.
The presentation discussed how a small molecule discovered by Tosk, partially restored normal wing development in the kRAS mutated flies and inhibited growth and signal transduction in multiple, oncogenic kRAS-driven cell lines. The goal of the successful collaboration between Tosk, NCI’s Frederick Laboratory, and TTHSC was to establish the mechanism-of-action of the discovered inhibitor. The work at Tosk and TTHSC was funded by an SBIR grant from NCI.
Dr. William Garland, Vice President of Research and Development at Tosk stated, “This innovative work on the discovered inhibitor provided important information on the previously, not fully appreciated, interplay between mutated kRAS and a metabolic process. The information gained will help future work at Tosk. The results demonstrate the power of collaboration among a small research company, academia, and a large public research institute. None of the groups alone could have achieved the advance reported in our joint presentation.”
About Tosk, Inc.
Tosk’s mission is to improve outcomes for cancer patients by discovering and developing new drugs that selectively block the adverse side effects of cancer therapies and make certain drugs effective in patients that currently do not benefit from treatment. Tosk uses proprietary drug screening methods using the common fruit fly to discover new drugs that might not be found using more conventional methods.

Brian Frenzel
Tosk, Inc.
+1 408-245-6838
email us here


Source: EIN Presswire

Ari Carlson of Arbonne International to be Featured on CUTV News Radio

EAGLE, IDAHO, UNITED STATES, December 13, 2018 /EINPresswire.com/ — A monthly salary is hardly enough to get by anymore. An extra $500 or $1000 a month can make a big difference That’s why it has become so important for people to have a secondary source of income.

One of the most popular ways to generate secondary income is through multilevel marketing companies. Also known as affiliated or network marketing, multilevel marketing companies utilize a network of independent distributors to deliver their products or services to the customers who want them, providing a platform to fast track business success.

Ari Carlson is a regional vice president of Arbonne International, a multilevel marketing company that specializes in the manufacture and distribution of health and skincare products.

“What drew me to Arbonne is I always had an entrepreneurial bug in me,” says Ari. “I had worked for a Fortune 100 company, climbed the corporate ladder with success, but I just never felt really fulfilled in that corporate career. When I quit to be home with my kids, I was looking for something that was flexible and I would enjoy. This business model allows me to be an entrepreneur and I can build it as big or as I wanted that's what drew me to it. When I started to have dramatic, noticeable results with the products, I knew I was where I was meant to be.”

Ari says one of the biggest concerns people have when they're evaluating whether this business can be a fit for them is whether they know enough people, but Ari says it doesn't really matter who you know today. If you have a desire to succeed, you find the people. Fortune is in the follow-up.

Still, you don't want to be intrusive; accosting people in the skincare aisle of your local supermarket is not the way to go. Not everyone walking down the street is a good fit for your business or your products. The only way to truly to succeed is to be genuinely interested in people, with no agenda.

“If you're genuinely interested in people, you're going to hear them share their dreams and desires. That provides an opportunity to say, ‘Hey, I have something that can help,’” says Ari. “When you're out networking, you have to do it with an authenticity. You are intentionally looking to meet new people, but not with dollar signs in your eyes. More I'm looking for people who are looking for me. I have to get out there and meet people or I'm not going to find them.”

Ari says the key to success in network marketing is to continuously nurture relationships.

“Some people come in with a lot of confidence it and some people come in with almost none of it. There's a learning curve, but I think that one of the things this industry offers in general and which Arbonne does really well is personal growth,” says Ari. “There's so much mentoring and coaching that you receive from really highly successful people who have your best interest at heart. One of the beautiful things about this business is that then adds value to every area of your life.”

CUTV News Radio will feature Ari Carlson in an interview with Jim Masters on December 17th at 3pm EST.

Listen to the show on BlogTalkRadio

If you have a question for our guest, call (347) 996-3389.

For more information on Ari Carlson, visit www.aricarlson.arbonne.com

Lou Ceparano
CUTV News
(631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire